Srivastava U K
Indian J Physiol Pharmacol. 1981 Apr-Jun;25(2):151-7.
Norethisterone enanthate (N.E.) administered in repeated intramuscular doses was found to bring about by and large a dose-related inhibition of compensatory ovarian hypertrophy (COH) which follows after the surgical removal of one ovary in adult rats. The relative inhibition in the responsiveness of the remaining ovary to compensatory gonadotrophic stimulation leading to the COH was of the order of 14.2, 19.0, 26.3, 25.0 and 42.0% with 0.25, 0.50, 1.0, 2.0 and 4.0 mg doses of N.E., respectively. The ED50 was calculated to be of the order of 7.0 mg. There was no effect of the treatment on the weight of the pituitary at any dose, whatsoever. However, the treatment was found to induce a significant increase in the weight of the uterus and the adrenals at higher doses (2.0 and 4.0 mg). The possibility of delineating the antigonadotrophic activity of activity of 'N.E.' from its contraceptive potential, vis-a-vis the dose employed, is discussed.
发现给成年大鼠反复肌内注射庚酸炔诺酮(N.E.)后,大体上会对代偿性卵巢肥大(COH)产生剂量相关的抑制作用,这种肥大是在成年大鼠一侧卵巢切除后出现的。随着N.E.剂量分别为0.25、0.50、1.0、2.0和4.0毫克,剩余卵巢对导致COH的代偿性促性腺激素刺激反应性的相对抑制程度分别约为14.2%、19.0%、26.3%、25.0%和42.0%。计算得出半数有效剂量(ED50)约为7.0毫克。无论何种剂量,该处理对垂体重量均无影响。然而,发现该处理在较高剂量(2.0和4.0毫克)时会使子宫和肾上腺重量显著增加。文中讨论了相对于所使用的剂量,从“N.E.”的避孕潜力中区分其抗促性腺激素活性的可能性。